Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer
Condition: Breast Cancer Interventions: Drug: Fluzoparib; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Tamoxifen; Drug: Toremifene; Drug: Abemaciclib; Drug: LHRH agonist Sponsor: Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Research | Tamoxifen